Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P08686
UPID:
CP21A_HUMAN
Alternative names:
21-OHase; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 XXI; Cytochrome P450-C21; Cytochrome P450-C21B
Alternative UPACC:
P08686; A2BHY6; P04033; Q01204; Q08AG8; Q16749; Q16806; Q5ST44; Q96NU8
Background:
Steroid 21-hydroxylase, known as Cytochrome P450 21, plays a pivotal role in adrenal steroidogenesis. It catalyzes the hydroxylation of progesterone and 17alpha-hydroxyprogesterone, crucial steps in the production of mineralocorticoids and glucocorticoids.
Therapeutic significance:
Mutations in Steroid 21-hydroxylase are linked to Adrenal hyperplasia 3, a condition characterized by defective cortisol synthesis leading to androgen excess. Understanding its role could lead to targeted therapies for this congenital adrenal hyperplasia.